Use of compound for treating heart failure with preserved ejection fraction
CA3318473A1Pending Publication Date: 2026-09-21BEIJING BAHEAL WISART MEDICAL RESEARCH CO LTD
0 Cites 0 Cited by
Patent Information
- Application Number
- CA3318473
- Authority / Receiving Office
- CA · CA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-25
- Filing Date
- 2025-01-21
- Publication Date
- 2026-09-21
AI Technical Summary
Technical Problem
Currently, effective drug therapy is lacking to treat ejection fraction-retained heart failure (HFpEF), which accounts for more than 50% of patients with heart failure and has high prevalence and mortality. Current drug therapy is limited.
Method used
The Jun inhibitors compounds T3 and T5 are used to treat and prevent heart failure with ejection fraction retention by inhibiting Jun's binding activity and transcriptional activity to DNA. The compounds can be administered orally or intravenously, combined with other active ingredients.
Benefits of technology
Compounds T3 and T5 significantly inhibit Jun's activity, can effectively prevent and treat HFpEF, showing faster therapeutic effects and better therapeutic advantages than existing positive control T-5524.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to a use of a compound for treating heart failure with preserved ejection fraction, and particularly provides a use of a compound or a stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, pharmaceutically acceptable ester, or pharmaceutically acceptable solvate thereof in the preparation of a drug for treating and / or preventing heart failure with preserved ejection fraction, wherein the compound is selected from T3 and T5.
Need to check novelty before this filing date? Find Prior Art